# MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is an Asset Manager based in Zug, Switzerland.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Zug, Switzerland
- **Region:** Europe
- **Address:** Zug, Switzerland
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** moonlaketx.com
- **LinkedIn:** https://www.linkedin.com/company/moonlake-immunotherapeutics-ag

## Regulatory record

- **Reports private funds:** No

## About

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company based in Zug, Switzerland, founded in 2021. It develops medicines for immunologic diseases using Nanobody technology. The company has secured 115 million in total funding.

## Sectors

- Biotechnology

## People

- Jorge Santos da Silva — Chief Executive Officer

## Questions

### What is MoonLake's lead therapeutic candidate?

MoonLake's sole clinical asset is sonelokimab, a trivalent nanobody that inhibits both IL-17A and IL-17F. The drug was originally developed by Merck KGaA and licensed by MoonLake at the time of its founding in 2021. It is being tested primarily for hidradenitis suppurativa and psoriatic arthritis, two chronic inflammatory conditions affecting large patient populations.

### How is MoonLake structured from a capital perspective?

MoonLake is a Nasdaq-listed clinical-stage biotech company, not a fund or family office. All capital is deployed directly into clinical development, with no external portfolio investments. The company raised initial funding through a reverse merger with a special-purpose acquisition company in 2021 and subsequently accessed public equity markets to fund Phase 3 trials.

### What are the key differentiation claims for sonelokimab?

The company claims its nanobody technology allows for higher potency per dose and better tissue penetration than existing monoclonal antibodies targeting the IL-17 pathway. Sonelokimab's small size and high solubility enable higher-concentration formulations for subcutaneous delivery. These pharmacological properties are the mechanistic basis for MoonLake's head-to-head comparisons with established IL-17 inhibitors.

### Who leads the clinical development team at MoonLake?

Jorge Santos da Silva is the Chief Executive Officer and the architect of MoonLake's founding strategy to acquire and advance a deprioritized Merck KGaA asset. Specific scientific leadership details beyond the CEO are not extensively publicized, but the firm relies on a network of contract research organizations and academic investigators for trial execution.

## Related profiles

- [Lindblad Expeditions Holdings](https://altss.com/profile/lindblad-expeditions-holdings-inc)
- [Versamet Royalties Corp](https://altss.com/profile/versamet-royalties-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/moonlake-immunotherapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology